Page 137 - ILAE_Lectures_2015

33. PANAYIOTOPOULOS CP, OBEID T, TAHAN AR. Juvenile myoclonic epilepsy: a 5-year prospective study.
Epilepsia 1994; 35:285-296.

34. GRUNEWALD RA, PANAYIOTOPOULOS CP. Juvenile myoclonic epilepsy. Arch Neurol 1993; 50:594-598.
35. GILLIAM F, STEINHOFF BJ, BITTERMANN HJ et al. Adult myoclonic epilepsy: a distinct syndrome of

idiopathic generalized epilepsy. Neurology 2000; 55:1030-1033.
36. TASSINARI CA, MICHELUCCI R, RUBBOLI G et al. Myoclonic absence epilepsy. In: Duncan JS,

Panayiotopoulos CP, eds. Typical Absences and Related Epileptic Syndromes. London: Churchill
Communications Europe, 1995: 187-195.
37. MANONMANI V, WALLACE SJ. Epilepsy with myoclonic absences. Arch Dis Child 1994; 70:288-290
38. JANZ D. Pitfalls in the diagnosis of grand mal on awakening. In: Wolf P, ed. Epileptic seizures and syndromes.
London: John Libbey & Company Ltd, 1994: 213-220.
39. JANZ D. Epilepsy with grand mal on awakening and sleep-waking cycle. Clin Neurophysiol 2000; 111 Suppl
2:S103-S110.
40. APPLETON RE, PANAYIOTOPOULOS CP, ACOMB BA et al. Eyelid myoclonia with typical absences: an
epilepsy syndrome. J Neurol Neurosurg Psychiatry 1993; 56:1312-1316.
41. GIANNAKODIMOS S, PANAYIOTOPOULOS CP. Eyelid myoclonia with absences in adults: a clinical and
video- EEG study. Epilepsia 1996; 37:36-44.
42. PANAYIOTOPOULOS CP, FERRIE CD, GIANNAKODIMOS S et al. Perioral myoclonia with absences: a new
syndrome. In: Wolf P, ed. Epileptic Seizures and Syndromes. London: John Libbey & Company Ltd, 1994: 143-
153.
43. BILGIC B, BAYKAN B, GURSES C et al. Perioral myoclonia with absence seizures: a rare epileptic syndrome.
Epileptic Disord 2001; 3:23-27.
44. PANAYIOTOPOULOS CP. A clinical guide to epileptic syndromes and their treatment. Oxford: Bladon Medical
Publishing, 2002.
45. BANCAUD J, TALAIRACH J. Clinical semiology of frontal lobe seizures. Adv Neurol 1992; 57:3-58.
46. RAYMOND AA, FISH DR, SISODIYA SM et al. Abnormalities of gyration, heterotopias,tuberous sclerosis,
focal cortical dysplasia,microdysgenesis,dysembryoplastic neuroepithelial tumour and dysgenesis of the
archicortex in epilepsy. Clinical, EEG and neuroimaging features in 100 adult patients. Brain 1995; 118:629-660.
47. FERRIE CD, GIANNAKODIMOS S, ROBINSON RO et al. Symptomatic typical absence seizures. In: Duncan
JS, Panayiotopoulos CP, eds. Typical Absences and Related Epileptic Syndromes. London: Churchill
Communications Europe, 1995: 241-252.
48. NORTH KN, OUVRIER RA, NUGENT M. Pseudoseizures caused by hyperventilation resembling absence
epilepsy. J Child Neurol 1990; 5:288-294.
49. COVANIS A, SKIADAS K, LOLI N et al. Absence epilepsy: early prognostic signs. Seizure 1992; 1:281-289
50. WIRRELL E, CAMFIELD C, CAMFIELD P et al. Prognostic significance of failure of the initial antiepileptic
drug in children with absence epilepsy. Epilepsia 2001; 42:760-763.
51. APPLETON RE, BEIRNE M. Absence epilepsy in children: the role of EEG in monitoring response to treatment.
Seizure 1996; 5:147-148.
52. DUNCAN JS. Antiepileptic drugs and the electroencephalogram. Epilepsia 1987; 28:259-266.
53. VILLARREAL HJ, WILDER BJ, WILLMORE LJ et al. Effect of valproic acid on spike and wave discharges in
patients with absence seizures. Neurology 1978; 28:886-891.
54. DAVIS R, PETERS DH, MCTAVISH D. Valproic acid. A reappraisal of its pharmacological properties and
clinical efficacy in epilepsy. [Review] [270 refs]. Drugs 1994; 47:332-372.
55. BERKOVIC SF, ANDERMANN F, GUBERMAN A et al. Valproate prevents the recurrence of absence status
[see comments]. Neurology 1989; 39:1294-1297.
56. VERROTTI A, GRECO R, CHIARELLI F et al. Epilepsy with myoclonic absences with early onset: a follow-
up study. J Child Neurol 1999; 14:746-749.
57. ACHARYA S, BUSSEL JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000; 22:62-65
58. BRYANT AE, III, DREIFUSS FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986 [see
comments]. Neurology 1996; 46:465-469.
59. CRAWFORD P, APPLETON R, BETTS T et al. Best practice guidelines for the management of women with
epilepsy. The Women with Epilepsy Guidelines Development Group. Seizure 1999; 8:201-217.
60. LAEGREID L, KYLLERMAN M, HEDNER T et al. Benzodiazepine amplification of valproate teratogenic
effects in children of mothers with absence epilepsy. Neuropediatrics 1993; 24:88-92.
61. CHAPPELL KA, MARKOWITZ JS, JACKSON CW. Is valproate pharmacotherapy associated with polycystic
ovaries? Ann Pharmacother 1999; 33:1211-1216.
62. GENTON P, BAUER J, DUNCAN S et al. On the association between valproate and poycystic ovary syndrome.
Epilepsia 2001; 42:295-304.
63. HERZOG AG, SCHACHTER SC. Valproate and polycystic ovarian syndrome: Final thoughts. Epilepsia 2001;
42:311-315.
64. LERMAN-SAGIE T, WATEMBERG N, KRAMER U et al. Absence seizures aggravated by valproic acid.
Epilepsia 2001; 42:941-943.
65. SATO S, WHITE BG, PENRY JK et al. Valproic acid versus ethosuximide in the treatment of absence seizures.
Neurology 1982; 32:157-163.
66. GERICKE CA, PICARD F, SAINT-MARTIN A et al. Efficacy of lamotrigine in idiopathic generalized epilepsy
syndromes: a video-EEG-controlled, open study. Epileptic Disord 1999; 1:159-165.
67. CULY CR, GOA KL. Lamotrigine. A review of its use in childhood epilepsy. Paediatr Drugs 2000; 2:299-330.
68. BIRABEN A, ALLAIN H, SCARABIN JM et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine.
Neurology 2000; 55:1758.
69. GUBERMAN AH, BESAG FM, BRODIE MJ et al. Lamotrigine-associated rash: risk/benefit considerations in
adults and children. Epilepsia 1999; 40:985-991.